BioAtla Inc - Company Profile
Powered by 
All the data and insights you need on BioAtla Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date BioAtla Inc Strategy Report
- Understand BioAtla Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
BioAtla Inc (BioAtla) is a clinical-stage biopharmaceutical company that develops novel therapies for the treatment of solid tumor cancer. The company product candidate includes BA3011, BA3021 and BA3071, BA3182, BA3142, BA3311, BA336 and BA3151. BioAtla lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate (ADC) that targets AXL, which is a protein kinase receptor. Its BA3021 is developing a CAB antibody-drug conjugate directed against receptor tyrosine kinase such as orphan receptor 2 (ROR2), BA3071 is therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer and cervical cancer. BioAtla is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
11085 Torreyana Road, San Diego, California, 92121
Website
www.bioatla.com
Telephone
1 858 5580708
No of Employees
65
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BCAB (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-15.9%
(2022 vs 2021)
Market Cap*
$122.2M
Net Profit Margin (2020)
XYZ
-356.6%
(2022 vs 2021)
* As of and is in US$
BioAtla Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Antibody Drug Conjugates (ADC's) | Bioatla |
| Monoclonal Antibodies (MAB's) | Conditionally Active Biologics (CAB) |
| Pipeline: | Comprehensive Integrated Antibody Optimization |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In February, the company announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application to evaluate BA3182 for the treatment of advanced adenocarcinoma. |
| 2022 | Contracts/Agreements | In January, the company entered into a clinical collaboration with Bristol Myers Squibb to investigate BioAtla's two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb's anti-PD-1 therapy Opdivo. |
| 2020 | Stock Listings/IPO | In November, the company announced to raise US$100 million in an initial public offering of shares. |
Competitor Comparison
| Key Parameters | BioAtla Inc | CytomX Therapeutics Inc | Chinook Therapeutics Inc | CerFlux Inc | Cogent Biosciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Diego | South San Francisco | Seattle | Birmingham | Waltham |
| State/Province | California | California | Washington | Alabama | Massachusetts |
| No. of Employees | 65 | 120 | 214 | - | 164 |
| Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jay M. Short | Chief Executive Officer; Chairman | Executive Board | 2020 | 65 |
| William Boyle | Director | Executive Board | 2021 | 67 |
| Richard A. Waldron | Chief Financial Officer | Senior Management | 2013 | 69 |
| Eric L. Sievers | Chief Medical Officer | Senior Management | 2019 | 59 |
| Chris Vasquez | Controller; Controller - Finance; Secretary; Senior Vice President - Finance | Senior Management | 2015 | 47 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer